How much does Keytruda cost for Medicare patients?
Keytruda (pembrolizumab) is an infusion cancer drug, and the out-of-pocket cost for Medicare depends mostly on which Medicare plan type a patient has (Original Medicare vs. Medicare Advantage) and whether the drug is billed under Part B (physician-administered) or covered through an Advantage plan’s prescription benefit. Medicare doesn’t publish a single “Medicare price” that applies to everyone, because the final amount reflects pricing negotiated by providers, insurers, and the specific billing setup for the infusion.
Does Keytruda fall under Medicare Part B or Part D?
For most patients getting Keytruda administered in a clinical setting, it is commonly treated as a physician-administered drug under Medicare Part B rather than Part D. That matters because:
- Part B typically includes the Medicare Part B deductible and then cost-sharing rules set by the plan/provider billing.
- Part D rules generally apply to retail pharmacy prescription coverage, which is less typical for infused administration.
Because coverage and billing can vary by site of care and plan design, patients usually need to confirm with their oncologist’s infusion billing team and their specific Medicare plan.
What determines the Medicare out-of-pocket cost (coinsurance, supplemental plan, and infusion setting)?
The patient’s Keytruda cost under Medicare is influenced by:
- Whether the drug is billed under Part B or through Medicare Advantage pharmacy benefits.
- The patient’s coverage gap status (mainly if it is treated as a Part D drug under their plan).
- Whether the patient has Medigap (supplemental insurance) to reduce coinsurance and deductibles.
- The contracted rate between the infusion provider and the payer/plan.
Even when the “list price” is widely reported, actual patient cost is driven by these negotiated and billing-specific factors.
Is there a cheaper alternative on Medicare or other programs?
Patients often lower net cost by switching to a different therapy only if it is clinically appropriate for the cancer type and stage. Some patients also reduce cost through:
- Medicare Advantage plans with different formularies/cost sharing
- Manufacturer patient assistance or copay support programs (eligibility depends on income and insurance type)
- Infusion-site billing programs and prior authorization processes
If you share the cancer type and whether the patient has Original Medicare or Medicare Advantage, the likely cost pathway (Part B vs plan rules) becomes easier to pin down.
Where can I find current Keytruda pricing and coverage-related updates?
For ongoing pricing, market context, and patent-related drug competition (which can affect pricing and access over time), DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/